Xeris Pharmaceuticals

Xeris Biopharma reported Q2/2026 revenue of $92.1 million, topping consensus, but reported EPS of -$0.18 versus an expected $0.01 due to a one-time, non‑cash GAAP charge from the revaluation of convertible notes. Net product revenue growth was driven mainly by RECORLEV (net $56.8M, +81% YoY) and a recovery at Gvoke; adjusted EBITDA rose to $19.3M. Xeris raised its full-year revenue guidance to $385–390M but forecast higher SG&A and R&D expenses, including spending to prepare Phase III trials of XP-8121. In July the company redeemed $34M of convertible notes, lowering interest costs; however, investors reacted cautiously premarket to the earnings miss. » Más en de.investing.com

The board of directors of Xeris appointed CEO John Shannon effective July 1, 2026, as chairman of the board; Marla Persky remains the lead independent director. At the same time, Dr. Nerissa Kreher was appointed to the board, which is thereby expanded to eight members. Under Shannon’s leadership, revenue in the last twelve months rose 41% to $315 million, the stock delivered a one‑year return of 66%, and market capitalization is about $1.34 billion. » Más en de.investing.com

The US Patent and Trademark Office has issued a notice of allowance for Xeris’ Keveyis patent application (No. 17/151,405); after completion of administrative steps, the patent is expected to protect Keveyis through 2039. Xeris plans to submit the patent to the FDA for listing in the Orange Book. The company recently reported revenue growth of 41% to $315 million and a gross margin of 86%, is profitable according to analysis, and shows analysts’ expectations for further earnings growth. » Más en de.investing.com